AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “hold” rating restated by investment analysts at Piper Jaffray Companies in a research note issued to investors on Thursday. They currently have a $15.00 price target on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price objective would indicate a potential upside of 13.21% from the stock’s previous close.

A number of other research firms have also recently issued reports on AMAG. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Wednesday, October 4th. Cantor Fitzgerald reiterated a “hold” rating and issued a $21.00 target price on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Janney Montgomery Scott reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. ValuEngine upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, B. Riley reissued a “hold” rating and set a $16.00 price target on shares of AMAG Pharmaceuticals in a research note on Tuesday. Twelve equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $21.00.

AMAG Pharmaceuticals (NASDAQ AMAG) traded down $0.70 during trading on Thursday, reaching $13.25. The company’s stock had a trading volume of 797,989 shares, compared to its average volume of 825,392. AMAG Pharmaceuticals has a 1 year low of $11.93 and a 1 year high of $25.20. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. The company has a market capitalization of $467.57, a PE ratio of -2.18 and a beta of 0.79.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative return on equity of 0.64% and a negative net margin of 35.35%. research analysts forecast that AMAG Pharmaceuticals will post -4.17 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the stock. Hartford Investment Management Co. acquired a new position in shares of AMAG Pharmaceuticals in the third quarter worth approximately $186,000. Cubist Systematic Strategies LLC acquired a new position in shares of AMAG Pharmaceuticals in the third quarter worth approximately $197,000. 361 Capital LLC acquired a new position in shares of AMAG Pharmaceuticals in the third quarter worth approximately $197,000. Aperio Group LLC acquired a new position in shares of AMAG Pharmaceuticals in the third quarter worth approximately $198,000. Finally, Municipal Employees Retirement System of Michigan lifted its stake in shares of AMAG Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock worth $243,000 after acquiring an additional 4,870 shares during the period.

ILLEGAL ACTIVITY NOTICE: “AMAG Pharmaceuticals (AMAG) Stock Rating Reaffirmed by Piper Jaffray Companies” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/18/amag-pharmaceuticals-amag-stock-rating-reaffirmed-by-piper-jaffray-companies.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.